Answers are grounded in this paper and cite their sources.
CSPG4 overexpression predicts poor survival in hepatocellular carcinoma, suggesting improved risk assessment for personalized treatment strategies.
CSPG4 overexpression serves as an oncogenic driver and independent predictor of poor survival in HCC. Combining CSPG4 expression with established clinical variables presents a more precise risk assessment tool for individuals with HCC after hepatectomy, offering new insights for personalized treatment strategies and outcome prediction in HCC.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: